Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Evivo
- Development stage
- Unknown
- Lead developer
- Evolve BioSystems
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Evivo is a proprietary live biotherapeutic product containing the probiotic strain Bifidobacterium longum subsp. infantis EVC001 (B. infantis EVC001). It is designed for use in newborns and infants to establish a healthy gut microbiome and support immune function[1][4][6]. The mechanism of action involves the unique ability of B. infantis EVC001 to efficiently capture, consume, and metabolize Human Milk Oligosaccharides (HMOs) from breast milk, which allows it to colonize the infant gut effectively[4][9]. This colonization helps reduce potentially pathogenic bacteria by altering gut biochemistry, lowering intestinal inflammation, and supporting digestive health[6][9]. Clinical research shows that Evivo improves breast milk digestion, reduces colic-associated symptoms such as gas and fussiness, decreases diaper rash incidence, improves sleep quality in infants, and supports overall immune health[4][7].
- Brand names
- Evivo
- Other names
- bifidobacterium longum subsp. infantis EVC001B. infantis EVC001
Beyond the preview
Go deeper on Evivo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Evivo.